» Welcome
You need to download the latest Flash player
Download here »
Or you can bypass the detection if you wish
What is a webcast?
Consensus on the management of cardiovascular risk in primary care
| A summary for general practice | Consensus on the management of cardiovascular risk in primary care - Highlights from 29th January 2008 | June 2008 | |||
| Presentation on CV risk calculation (including QRISK) by Professor Paul Durrington, followed by panel discussion | June 2008 | ||||
| Presentation on the management of patients with CV risk by Professor Mike Kirby | June 2008 | ||||
| Panel discussion leading to a consensus on the management of patients with CV risk | June 2008 | ||||
| Consensus statement on the management of patients with CV risk by Dr Mark Davis | June 2008 |
Cholesterol targets 4&2 mmol/L: a debate
| Highlights from the British Cardiovascular Society Annual Scientific Conference | Introduction from the chairman Professor Neil Poulter Organised and funded by Pfizer | June 2008 | |||
| The case ‘for’ presented by Dr Anthony Wierzbicki Organised and funded by Pfizer | June 2008 | ||||
| The case 'against' presented by Professor Richard Hobbs Organised and funded by Pfizer | June 2008 | ||||
| Panel debate and results from a vote on the motion Organised and funded by Pfizer | June 2008 |
Multiple sclerosis: an essential guide for the primary care team
| Multiple sclerosis: an essential guide for the primary care team | Multiple sclerosis: an essential guide for the primary care team Presented by Professor Gavin Giovannoni and Dr James Overell | March 2008 | |||
| Q&A with Professor Gavin Giovannoni | May 2008 | ||||
| Q&A with Dr James Overell | May 2008 |
Question time: 4&2 mmol/L - does it have a place in clinical practice?
| 4 & 2mmol/L in diabetes: does it have a place in primary care? Dr Mark Davis Organised and Funded by Pfizer | January 2008 | ||||
| 4 & 2mmol/L in diabetes: does it have a place in secondary care? Professor John Betteridge Organised and Funded by Pfizer | January 2008 | ||||
| Panel Discussion and vote on the motion Organised and Funded by Pfizer | January 2008 |
Treating overactive bladder
| Vik Khullar - Treating overactive bladder | March 2008 |
Assessing overactive bladder
| Katherine Wilkinson - Assessing overactive bladder | December 2007 |
Community continence care clinics
| Dr Adrian Wagg - Community continence care clinics | November 2007 |
Question Time: PCCS, looking to the future
| Ask the Experts | September 2007 |
Legal Basis of Vaccine Prescribing: Current Challenges in Primary Care - Dec 2006
| Legal Basis of Vaccine Prescribing | Jeannett Martin, Judith Moreton and Jackie Moss | Full presentation | 13 December 14:00 | |
| Introduction | 13 December 14:00 | |||
| Section 1: Patient Specific / Group Directions | 13 December 14:00 | |||
| Section 2: Legislation and Legal Liabilities | 13 December 14:00 | |||
| Section 3: Training Resources | 13 December 14:00 | |||
| Live Q&A Session | 10 January 12:00 |
Reducing risk in cardiovascular disease: JBS2 - Achieving goals and targets
| Reducing risk in cardiovascular disease: JBS2 - Achieving goals and targets | Professor Mike Kirby | Presentation | 30 May 14:00 | |
| Q&A Session 1 | 30 May 14:30 | |||
| Q&A Session 2 | 06 June 12:00 | |||
| Q&A Session 3 | 13 June 15:00 | |||
| Q&A Session 4 | 20 June 15:00 | |||
| Q&A Session 5 | 30 June 14:30 |
Practice Based Commissioning - Presentation and Q&A sessions
| Practice Based Commissioning | Dr. Stewart Findlay | Presentation | 08 August 14:00 | |
| Q&A Session 1 | 08 August 14:20 | |||
| Q&A Session 2 | 15 August 14:30 | |||
| Q&A Session 3 | 22 August 14:30 | |||
| Q&A Session 4 | 14 September 15:00 |
CVD Risk Reduction: An essential guide for the primary care team – Nov 2006
| CVD Risk Reduction | Dr. Mark Davis | Presentation | 20 November 14:00 | |
| Q&A Session 1 | 20 November 14:30 | |||
| Q&A Session 2 | 27 November 14:30 | |||
| Q&A Session 3 | 04 December 14:30 | |||
| Q&A Session 4 | 14 December 12:00 |
Unmet needs in Osteoporosis management
| Mike Stone | Presentation | 26 February 12:30 |
Bisphosphonates: first line defence against Osteoporosis
| Philip Sambrook Sponsored by Roche & GSK | Presentation | 26 February 12:30 |
The reality for patients who fail on oral therapy
| Norma Rowland and Neil Gittoes Sponsored by Roche & GSK | Presentation | 12 March 12:30 |
A cholesterol target of 4&2 mmol/L: The 'for' and 'against' debate
| Opening remarks by Profesor Bryan Williams Organised and funded by Pfizer | 06 April 12:30 | |||
| Dr Jonathan Morrell speaks FOR the need for cholesterol targets of 4&2 mmol/L in clinical practice Organised and funded by Pfizer | 06 April 12:30 | |||
| Professor Richard Hobbs speaks AGAINST the need for cholesterol targets of 4&2 mmol/L in clinical practice. Dr Kausik Ray speaks FOR the need for cholesterol targets of 4&2 mmol/L in clinical practice Oragnised and funded by Pfizer | 06 April 12:30 | |||
| Q&A session Guest panel members and Professor Bryan Williams Oragnised and funded by Pfizer | 06 April 12:30 | |||
| Vote and Close Professor Bryan Williams Oragnised and funded by Pfizer | 06 April 12:30 |
